Biofrontera Reports 33% Revenue Growth and Nears Cash Flow Breakeven as Ameluz PDT Pipeline Advances
核心洞察
Biofrontera Inc. reported second quarter 2026 net product revenue of $12.0 million, a 32.9% increase over the prior-year period, driven by Ameluz unit volume growth and a price increase.
Gross margin improved to 80% from 71% year over year, reflecting the lower Ameluz cost structure established after the strategic transaction with Biofrontera AG.
The company has a PDUFA date in late September 2026 for Ameluz in superficial basal cell carcinoma (搜索), which would make it the first PDT approved in the U.S. for cancerous tumors.
Biofrontera Inc. (NASDAQ: BFRI), a biopharmaceutical company specializing in photodynamic therapy (PDT) for dermatology, reported its strongest operating quarter and first half in company history as a standalone business, with second quarter 2026 net product revenue of $12.0 million, an increase of 32.9% compared to $9.0 million in the prior-year period.
"This was the strongest operating Q2 and H1 in the Company's history as a standalone business, and it reflects work that has been underway for more than a year - a restructured cost base, a more disciplined commercial organization, and steady growth in Ameluz demand," said Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera. "We are seeing the pace of reorders accelerate, which reflects strength of underlying demand."
Financial Performance Driven by Restructured Cost Base
Gross margin reached 80% in the second quarter, compared to 71% in the prior-year period, an improvement of approximately 920 basis points. The company attributed this expansion to the lower Ameluz cost structure established following the closing of the strategic transaction with Biofrontera AG in October 2025, which transitioned the company from a prior transfer pricing arrangement to a cost structure comprising Ameluz direct cost plus a 12% earnout on net revenue.
Net loss narrowed to $0.6 million, or $(0.05) per share, compared to a net loss of $5.3 million, or $(0.57) per share, in the prior-year period. Adjusted EBITDA improved to $(0.2) million from $(5.1) million, an improvement of approximately $5.0 million.
"We see positive effects from the Strategic Transaction and our overall cost management, the impacts of which are now visible in the Q2 results," said Fred Leffler, Chief Financial Officer. "Gross margin improved roughly 920 basis points year over year, operating expenses declined 11%, and we brought Adjusted EBITDA to within $0.2 million of breakeven."
For the first half of 2026, net product revenue was $22.1 million, an increase of 25.4% from $17.6 million in the prior-year period. Gross margin was 80%, compared to 67% in the prior-year period. Net loss was $5.4 million, or $(0.44) per share, compared to a net loss of $9.5 million, or $(1.05) per share, in the prior-year period. Cash used in operating activities was $1.7 million, compared to $7.2 million in the prior-year period, a reduction of approximately 76%.
Regulatory Milestones and Pipeline Expansion
The company highlighted several advancing indications in its development pipeline. For superficial basal cell carcinoma (搜索) (sBCC), Biofrontera has a PDUFA date in late September 2026 and expects to launch in the first quarter of 2027. "If approved for sBCC, Ameluz will be the first PDT in the United States approved for the treatment of cancerous tumors," Luebbert stated.
The clinical pipeline also includes recent positive Phase III results in actinic keratosis (搜索) (AK) on the extremities, neck, and trunk, as well as encouraging Phase 2B data in acne. Luebbert noted these developments "can expand the reach of our PDT platform in the years ahead."
Supply Chain Considerations
The company disclosed that part of the second quarter revenue increase was driven by the impact of order timing from certain customers in anticipation of potential supply restrictions resulting from an exclusion order by the International Trade Commission (ITC) related to its RhodoLED XL lamp, which took effect on July 7, 2026. Biofrontera stated it is pursuing a remediation plan to allow it to begin selling a modified version of its XL lamp.
"Because the substantial majority of our installed lamp base is unaffected by the ITC order, any shift in orders to the second quarter from the second half of the year is not expected to impact our full-year 2026 revenue goals," the company stated.
Balance Sheet and Liquidity
Cash and cash equivalents were $4.7 million as of June 30, 2026, compared to $6.4 million as of December 31, 2025. Total liabilities were $18.1 million, essentially unchanged from year-end. The company's outstanding indebtedness consisted of $4.6 million of convertible notes, net, maturing in November 2027, with no bank or other term debt. Total stockholders' equity was $6.0 million as of June 30, 2026, compared to $10.5 million at December 31, 2025.
Leffler noted the company continues to make progress toward cash flow breakeven in 2026, adding that the first half operating cash figure included a $3.7 million paydown of related party payables connected to the Strategic Transaction. "Excluding that item, changes in working capital would have been a net source of cash in the first half," he said.